^
    Back
    Association details:
    Biomarker:FCGR2B expression
    Cancer:Diffuse Large B Cell Lymphoma
    Regimen:R-CHOP
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    Blood Adv
    Title:

    Prognostic significance of FCGR2B expression for the response of DLBCL patients to rituximab or obinutuzumab treatment

    Published date:
    08/10/2021
    Excerpt:
    ...DLBCL discovery cohorts treated with R plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP)...In the discovery cohorts, higher FCGR2B expression was associated with significantly shorter progression-free survival...
    DOI:
    10.1182/bloodadvances.2021004770
    Trial ID:
    GOYA